New data on pancreatic cancer;Neue Daten zum Pankreaskarzinom

Onkologie

Volumn 33, Issue SUPPL. 4, 2010, Pages 31-35

  Fietkau, Rainer ^a   Heinemann, Volker ^b   Oettle, Helmut ^c   Knoefel, Wolfram Trudo ^d   Tannapfel, Andrea ^e  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^e INSTITUT FÜR PATHOLOGIE   (Germany)

Author keywords

'High volume' pancreas centers; Adjuvant therapy; Erlotinib; Gemcitabine; Pancreatic cancer; R classification; Radiochemotherapy

Indexed keywords

ERLOTINIB; FLUOROURACIL; GEMCITABINE; OXALIPLATIN; SORAFENIB;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INFILTRATION; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; HISTOPATHOLOGY; HUMAN; PANCREAS CANCER; PERIOPERATIVE PERIOD; PORTAL VEIN; PROGNOSIS; SUPERIOR MESENTERIC ARTERY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; HUMANS; LYMPHATIC METASTASIS; NEOADJUVANT THERAPY; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; QUINAZOLINES; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77952305433     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000308453     Document Type: Conference Paper

References (21)

1. Verbeke CS, et al.: Resection margins and R1 rates in pancreatic cancer - are we there yet? Histopathology 2008;52:787-796.
2. Raut CP, et al.: Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007;246:52-60.
3. Campbell F, et al.: Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology 2009;55:277-283.
4. Chang DK, et al.: Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 2009;27:2855-2862.
5. Menon KV, et al.: Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford) 2009;11:18-24.
6. Hernandez J, et al.: Survival after pancreaticoduodenectomy is not improved by extending resections to achieve negative margins. Ann Surg 2009;250:76-80.
7. Ghaneh P, et al.: Neoadjuvant and adjuvant strategies for pancreatic cancer. Eur J Surg Oncol 2008;34:297-305.
8. Stocken DD, et al.: Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005;92:1372-1381.
9. Merchant NB, et al.: Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: who really benefits? J Am Coll Surg 2009;208:829-838; discussion 838-841.
10. Stessin AM, et al.: Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) registry. Int J Radiat Oncol Biol Phys 2008;72:1128-1133.
11. Golcher H, et al.: Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. Eur J Surg Oncol 2008;34:756-764.
12. Chauffert B, et al.: Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study. J Clin Oncol 2006 ASCO Ann Meeting Proc I 2006; 24 (suppl) : 18s, abstr 4008.
13. Huguet F, et al.: Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007;25:326-331.
14. Loehrer PJ, et al.: A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol 2008; 26 (suppl) : abstr 4506.
15. Regine WF, et al.: Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008;299:1019-1026.
16. Neuhaus P, et al.: CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol 2008; 26 (suppl) : abstr LBA4504.
17. Adler G, et al.: S3-Leitlinie «Exokrines Pankreaskarzinom» 2007. Z Gastroenterol 2007;45:487-523.
18. Boeck S, et al.: Current oncological treatment of patients with pancreatic cancer in Germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society. Oncology 2009;77:40-48.
19. Birkmeyer JD, et al.: Hospital volume andlate survival after cancer surgery. Ann Surg 2007;245:777-783.
20. Birkmeyer JD, et al.: Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128-1137.
21. Triano LR, et al.: New developments in the treatment of locally advanced pancreatic cancer. JOP 2009;10:366-372.